All the news

Showing 10 of 87 articles from: NAFLD

Get an RSS feed of these articles

Show

With NASH results, Intercept Pharma will seek approval for first-ever treatment for fatty liver condition

STAT / 19 February 2019
Gilead’s Liver-Drug Setback Clouds $35 Billion Dream

Bloomberg / 13 February 2019
Gilead rocked by phase 3 failure of selonsertib in NASH

Fierce BioTech / 13 February 2019
Experimental therapy improves liver health in people with fatty liver disease

Liz Highleyman / 31 January 2019

NGM282, an experimental fibroblast growth factor analogue, reduced liver fat build-up and the development of scar tissue in people with non-alcoholic steatohepatitis, according to studies presented at the recent AASLD Liver Meeting in ...
A Big, Fatty Opportunity for Big Pharma

Wall Street Journal / 18 January 2019
Take Home from NASH-TAG: On the precipice of the fatty liver pipeline

Healio / 18 January 2019
Aramchol reduces liver fat in people with NASH

Liz Highleyman / 02 January 2019

A novel type of experimental therapy led to a significant reduction in liver fat and improvement in liver health among people with non-alcoholic steatohepatitis (NASH), according to study presented at the recent AASLD Liver ...
Lean people can develop fatty liver disease

Liz Highleyman / 17 December 2018

Metabolically healthy lean people may develop non-alcoholic fatty liver disease (NAFLD), although this is much more common among people with obesity and metabolic abnormalities, according to research presented at the AASLD Liver ...
Why has liver disease in Britain reached 'almost epidemic' proportions?

Daily Telegraph / 17 December 2018
Burden of severe liver disease due to fatty liver will more than double by 2030

Keith Alcorn / 07 December 2018

If current trends in obesity and diabetes continue, at least 520 million people will be living with non-alcoholic fatty liver disease (NAFLD) in western Europe, China, Japan and the United States by ...